openPR Logo
Press release

Soaring Demand Drives Depression Drugs Market Growth during the Forecast Period, 2018 - 2026(Drivers and Restraints Snapshot Analysis:-Drivers,Restraints,Opportunities,Key Trends,Pipeline Analysis)

07-04-2019 01:57 PM CET | Advertising, Media Consulting, Marketing Research

Press release from: Fact.MR

/ PR Agency: Fact.MR
Soaring Demand Drives Depression Drugs Market Growth during

The depression drugs market, valued at over US$ 6.5 billion in 2017, is likely to witness bearishness in the near future, with a new report by Fact.MR estimating revenues to decline at a -2% CAGR. According to the study, although the prevalence rate of depression has gone up in the last decade, preference for cognitive behavior therapy (CBT) and awareness about the potential side effects has led to a decline in demand for depression drugs. The study finds that US continued to be at the forefront in terms of total depression drugs sold in 2018.

According to the World Health Organization (WHO), depression has become one of the common illnesses, affecting over 300 million people across the world. In the United States, approximately 10.3 million adults had experienced at least one major depressive episode that resulted in severe impairment, according to the National Institute of Mental Health (NIMH). High prevalence of such depressive episode was observed among people aged 18-25 (10.9%), female adults (8.5%), and male adults (4.8%).

Request Sample Report- https://www.factmr.com/connectus/sample?flag=S&rep_id=3215

According to the Fact.MR study, although depression continues to be a major health issue, medical community and patients are encouraging a non-drug approach to reduce side effects and dependency. Healthcare providers and patients are focusing on cognitive behavior therapy (CBT) and mindfulness-based approaches to foster a long-term management of depression and other mental health issues.

Popularity of Tech-based Mental Health Apps also Contributing to Low Sales

The study finds that demand for depression drugs is also witnessing a decline as end-users have more coping options at their disposal. The huge popularity of mental health apps, such as Headspace, Calm, Moodnotes, Pacifica, and SuperBetter has given patients more control over how they manage depression. Considering the growing body of research supporting the use of meditation and cognitive behavior therapy, the proliferation of tech apps has witnessed a spike in the recent years. The study finds that depression drugs market will continue to be influenced by these evolutions.

Depression Drugs Research Report Overview- https://www.factmr.com/report/3215/depression-drugs-market

Depression Drugs Market to Remain Concentrated in Developed Nations

North America and Europe are the two largest depression drugs market globally, owing to concentration of leading market players and increase in R&D of these drugs. While there has been a rising burden of mental illness such as bipolar I disorder and schizophrenia in China and India, lack of wide-ranging awareness regarding antidepressant medications (ADMs) is expected to negatively affect the growth of depression drugs market in the Asia Pacific region. Moreover, different therapies of depression are as efficacious as ADM and their effects are more enduring, which may create a hindrance in future expansion of depression drugs market, especially in Asia Pacific and Middle East & Africa.

Request Methodology- https://www.factmr.com/connectus/sample?flag=RM&rep_id=3215

Depression Drugs Market: Segment-wise Insights

On the basis of drug class, the global depression drugs market has been segmented into SSRIs, atypical antipsychotics, SNRIs, CNS stimulants, and others. Of these, atypical antipsychotics is expected to contribute the largest share in the market.
Major depressive disorder has been envisaged to account for the most substantial share in the depression drugs market based on disease type. Other sub-segments include SSRI induced, schizophrenia, and bipolar I disorder.
While depression drugs are sold across retail, hospital, and online pharmacies, the retail segment registered the largest share in 2017, and the trend is expected to continue during the 2018-2026 period.

Global Depression Drugs Market: Competitive Landscape

Some key players operating in the manufacturing of depression drugs are Otsuka Pharmaceutical Co., Ltd., Johnson & Johnson, Sebela Pharmaceutical Inc., GlaxoSmithKline plc, AstraZeneca plc, Eli Lilly and Company, Allergan USA, Inc., Takeda Pharmaceutical Company Ltd, Novartis AG, Pfizer, Inc., Alkermes Plc, H. Lundbeck, Bristol Myers Squibb Co., and Teva Pharmaceutical Industries Ltd.

To Buy Report, Visit- https://www.factmr.com/checkout/935/S

Contact Us
Rohit Bhisey
Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
Blog: https://factmrblog.com/

About US

Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Soaring Demand Drives Depression Drugs Market Growth during the Forecast Period, 2018 - 2026(Drivers and Restraints Snapshot Analysis:-Drivers,Restraints,Opportunities,Key Trends,Pipeline Analysis) here

News-ID: 1796662 • Views:

More Releases from Fact.MR

Vegan Flavors Market Is Slated To Reach US$ 18,324.3 Million At A CAGR Of 5.2% B …
The global vegan flavor market is estimated to be valued at US$ 11,078.2 million in 2024 and is forecast to reach a value of US$ 18,324.3 million by 2034, with a projected CAGR of 5.2% from 2024 to 2034 owing to the rising popularity of plant-based diets. The Vegan Flavor Industry sales study offers a comprehensive analysis on diverse features including production capacities, Vegan Flavor demand, product developments, sales revenue generation
Pesticide Inert Ingredients Market Is Projected To Reach A Value Of US$ 13,167.2 Million By 2034: Fact.MR Report
Pesticide Inert Ingredients Market Is Projected To Reach A Value Of US$ 13,167.2 …
The global pesticide inert ingredients market is estimated to attain a valuation of US$ 7,621.2 million in 2024. During the forecast period, 2024-2034, the demand for pesticide-inert ingredients is expected to advance at a 5.6% CAGR globally. By 2034, the industry is expected to have grown to a valuation of US$ 13,167.2 million in size. The Pesticide Inert Ingredients Industry sales study offers a comprehensive analysis on diverse features including production
Portable Bluetooth Speaker Market Is Projected To Reach A Value Of US$ 20,521 Million At A CAGR Of 10.6% By 2034
Portable Bluetooth Speaker Market Is Projected To Reach A Value Of US$ 20,521 Mi …
The global portable bluetooth speaker market is estimated to be valued at US$ 7,521.6 million in 2024. The market is anticipated to reach US$ 20,521 million by 2034, with a projected CAGR of 10.6% from 2024 to 2034. The Portable Bluetooth Speaker Industry sales study offers a comprehensive analysis on diverse features including production capacities, Portable Bluetooth Speaker demand, product developments, sales revenue generation and Portable Bluetooth Speaker market outlook
Atrial Fibrillation Device Market to Attain US$ 24.76 Billion at 14.3% CAGR by 2034: Fact.MR Report
03-29-2024 | Health & Medicine
Fact.MR
Atrial Fibrillation Device Market to Attain US$ 24.76 Billion at 14.3% CAGR by 2 …
The global atrial fibrillation devices market (心房細動装置市場) size stands at a valuation of US$ 6.52 billion in 2024, with forecasts predicting a surge to US$ 24.76 billion by the conclusion of 2034. Sales of atrial fibrillation devices worldwide are expected to witness an impressive compound annual growth rate (CAGR) of 14.3% from 2024 to 2034. In recent years, the global healthcare landscape has witnessed a significant surge in the prevalence of

All 5 Releases


More Releases for Depression

Increase in the prevalence of anxiety disorders and depression is bolstering the …
The research report "Global Anxiety Disorders and Depression Treatment Market: By Product Type (MAOIs (Monoamine Oxidase inhibitors), Atypical Antipsychotics, Benzodiazepines, Anticonvulsants, Beta-Blockers, SRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors), TeCAs (Tetracyclic Antidepressants), TCAs (Tricyclic Antidepressants), Others), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Others), and Geography- Global/Region/Country Forecast to 2028." The global anxiety disorders and depression treatment market size was valued at USD 8.2 Bn in the year
Depression Treatment Device Market: Information by Product Type (Light Therapies …
Depression is characterized by multiple mental health challenges that involve a lack of positivity, suicidal thoughts, insomnia, anxiety, loss of appetite, and sadness. Depression is caused by a combination of biological, genetic, environmental, and psychological factors. Globally, the prevalence of depression is increasing at an alarming rate. About 300 million people of all ages suffered from depression and the suicide rate rose to about 8,00,000 individuals in 2018. As per
Depression Cannot Hit A Moving Target
Cottonwood Heights, Utah, Mar 12, 2020 -- Depression can't hit a moving target. That was a phrase to live by for Chelsea Hansen. She was full of life and love, and she had big goals. But soon she was to discover that life doesn't turn out the way she planned. Behind the Fake Smile is a fictional book based on real-life experiences. It's the story of how Chelsea navigates a world
Depression Drugs Market: Increase in Cases of Depression to Boost Market Growth
Transparency Market Research (TMR) has published a new report titled, “Depression Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global depression drugs market was valued at US$ 6,500 Mn in 2017 and is anticipated to decline at a CAGR of 2% from 2018 to 2026. The report suggests that rise in incidence of major depression disorders is projected to drive
Depression Therapeutics Market Forecast till 2025
Antidepressants are used to treat a wide range of mental disorders, including depression, anxiety, and major depressive disorder. Certain neurotransmitters in the brain exist in chemical form such as dopamine and serotonin, which are responsible for maintaining emotional balance such as mood and behavior. Antidepressants cover a wide range of drug categories, including selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants
Depression Drug Market: Global Depression Drug Forecast Will Reach $16.8 billion …
Zion Market Research has published a new report titled “Depression Drug (Benzodiazepines, SNRIs, TCAs, TeCAs, Atypical Antipsychotics, Monoamine Oxidase inhibitors and Others) Market: Global Industry Perspective, Comprehensive Analysis and Forecast, 2014 – 2020” According to the report, the global depression drug market was valued at USD 14.51 billion in 2014 and is expected to generate revenue of USD 16.8 billion by end of 2020, growing at a CAGR of 2.50%